- Open Access
Correction to: Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective
© The Author(s). 2019
- Received: 16 January 2019
- Accepted: 16 January 2019
- Published: 28 January 2019
The original article was published in Respiratory Research 2018 19:224
Correction to: Respir Res
Reference 24 needs to be amended to 25
The 12-week study needs to be corrected to 8-week study
This study is the first to compare two LAMA/LABA dual therapies using direct head-to-head data from a randomized, 8-week study , which is the most reliable set of data to include within a cost-effectiveness model .
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Driessen, et al. Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective. Respir Res. 2018;19:224. https://doi.org/10.1186/s12931-018-0916-7.View ArticlePubMedPubMed CentralGoogle Scholar